GSK presents data from liver pipeline at AASLD 2025

GSK (GSK) will showcase latest advances in its liver pipeline, with 21 abstracts presented at the American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2025, taking place in Washington D.C., from 7 to 11 November, including data from two assets in late-stage clinical development, bepirovirsen and efimosfermin. Advancing bepirovirsen in chronic hepatitis B and efimosfermin in the treatment of MASH: Efimosfermin demonstrated sustained improvement in fibrosis and resolution of MASH in patients with stage F2/F3 disease severity up to 48 weeks. These data supported the start of the ZENITH-1 and ZENITH-2 phase III trials, investigating the efficacy and safety of efimosfermin in patients with moderate and advanced fibrosis due to MASH. Additional presentations demonstrate GSK’s progress in liver disease, addressing critical unmet needs: Data supporting linerixibat’s mechanism of action and safety profile in cholestatic pruritus, following the recent publication of the phase 3 GLISTEN study in Lancet Gastroenterology & Hepatology.